Navigation Links
Ceragenix Announces New Publication of Scientific Research on,Ceragenin Technology

cessful clinical trials of the company's planned products including; the ability to enroll the studies in a timely manner, patient compliance with the study protocol, and a sufficient number of patients completing the studies; the ability of the company to commercialize its planned products; the ability of the company to consummate a favorable marketing agreement with a partner to market EpiCeram(TM); market acceptance of the company's planned products, the company's ability to successfully develop its licensed compounds, alone or in cooperation with others, into commercial products, the ability of the company to successfully prosecute and protect its intellectual property, and the company's ability to hire, manage and retain qualified personnel. The aforementioned factors do not represent an all inclusive list. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained in this press release. In particular, important factors that could cause actual results to differ materially from the company's forward-looking statements include general economic factors, business strategies, the state of capital markets, regulatory conditions, and other factors not currently known to the company, may be significant, now or in the future, and these factors may affect the company to a greater extent than indicated. All forward-looking statements attributable to the company or persons acting on its behalf are expressly qualified in their entirety by the cautionary statements set forth in this press release and in other documents that the company files from time to time with the Securities and Exchange Commission including its Annual Report on Form 10-KSB for the year ended December 31, 2006, Quarterly Reports on Form 10-QSB and Current Reports on Form 8-KSB to be filed in 2007. Except as required by law, the company does not undertake any obligation to update any forward-looking statemen
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Ceragenix Compound Shows Promise for Treating Lethal Cystic Fibrosis Infections
2. Ceragenix Announces Results from Phase IV Study of EpiCeram Meet All Primary and Secondary Endpoints
3. Ceragenix Announces Ceragenins Virtually Prevent Catheter Biofilm Formation in 21 Day Study
4. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
(Date:7/1/2015)... DUBLIN , June 24, 2015 /PRNewswire/ ... http://www.researchandmarkets.com/research/34xqr7/2015_new ) has announced the addition of ... Clinical Chemistry and Immunodiagnostic Markets: Business Challenges, ... their offering. 2015 New Frontiers ... Business Challenges, Emerging Technologies, Competitive Landscape is ...
(Date:7/1/2015)... , June 24, 2015 ... announced the addition of the "2015 Strategies ... their offering. This new 175-page report ... segments, including diabetes (strips and meters), pregnancy, ovulation, ... size, growth, regulatory requirements, technologies, and competitive profiles. ...
(Date:7/1/2015)... 2015  Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY ... and commercialization of proprietary compounded drug formulations, today ... stock market closing bell on Thursday, July 2, ... its Go Dropless™ campaign since its launch in ... performed annually in the U.S. and more than ...
Breaking Medicine Technology:2015 New Frontiers in European Clinical Chemistry and Immunodiagnostic Markets: Business Challenges, Emerging Technologies, Competitive Landscape 22015 Strategies in the Home/Self Testing Market 2Imprimis Pharmaceuticals to Ring The Nasdaq Stock Market Closing Bell 2Imprimis Pharmaceuticals to Ring The Nasdaq Stock Market Closing Bell 3Imprimis Pharmaceuticals to Ring The Nasdaq Stock Market Closing Bell 4
(Date:7/1/2015)... (PRWEB) , ... July 01, 2015 , ... Sir Fazle ... annual World Food Prize today. Sir Fazle has been recognised for his outstanding contribution ... , Ambassador Ken Quinn, President of the World Food Prize Foundation, announced this ...
(Date:7/1/2015)... , ... July 01, 2015 , ... ... devoted exclusively to funding innovative lymphoma research and serving the lymphoma community through ... announced that they will welcome four new members to their industry leading Scientific ...
(Date:7/1/2015)... ... July 01, 2015 , ... DIC Corporation today announced the ... natural blue food coloring. Construction of the plant, which is located on the ... began in May 2014. After commissioning, commercial production is expected to begin in ...
(Date:7/1/2015)... ... July 01, 2015 , ... OncLive® ... Hospital Corporation of America (HCA), as it further expands its Strategic Alliance Partnership ... , With this new partnership, OncLive’s editorial and marketing teams will collaborate with ...
(Date:7/1/2015)... ... ... The 28th annual Charity Horse Show hosted by the Mid-South Horse Show Association ... Pugh Bourne Park, 343 Oakfield Road. The event will again benefit Youth Town. , ... silent auction and concessions. , Horses and riders from around the country will participate ...
Breaking Medicine News(10 mins):Health News:Sir Fazle Hasan Abed Receives World Food Prize 2Health News:Sir Fazle Hasan Abed Receives World Food Prize 3Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 2Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 3Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 4Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 5Health News:DIC Strengthens Its Position as the Global Leader for Natural Blue Food Coloring 2Health News:DIC Strengthens Its Position as the Global Leader for Natural Blue Food Coloring 3Health News:OncLive® Welcomes Sarah Cannon Cancer Network to Its Strategic Alliance Partnership Program 2Health News:OncLive® Welcomes Sarah Cannon Cancer Network to Its Strategic Alliance Partnership Program 3
... taken gigantic proportions not only in the animal world but human ... wanting to visit // countries with bird flu like China, Vietnam, ... moment the unanimous voice is to take the plunge as bird ... to worry., ,The infection in humans is due to close ...
... to India for the sake of low priced cosmetic ... waistline, rhinoplasty, and breast improvements are very expensive. // ... UK every year. ,Recent figures released ... that breast enlargement topped the list of cosmetic operations ...
... beset with administrative problems, experienced another upheaval. In a ... // Dr. Hart, the Director of the program for ... Dr Hart will still continue as a full-time surgeon ... ,The UC San Diego, disappointed with the manner in ...
... A domino transplant surgery was conducted through which 3-month-old Jason ... week old baby received a heart // transplant in Ohio. ... passed away, and its organs were compatible to the two ... ,The dead child’s heart and lungs were transplanted to ...
... Canada has been warned of fines by the Government if ... Copeman Healthcare intends to establish clinics in Ottawa, Toronto, and ... charging a joining fee of $1,200, and another $2,300 towards ... ,The medicare law of the state says a fine of ...
... President George W. Bush as called for complete banning on ... as asked to reduce the medical // liability system; the ... among the American people which has reduced the number of ... talk as urged the congress to approve a complete ban ...
Cached Medicine News:Health News:More People Come To India For Cosmetic Surgery 2
... The Auto Suture™ VERSAPORT™ PLUS RPF trocar ... mm long, 5 mm-11 mm, 5 mm-12 mm, ... sleeve and shield. , ,The VERSAPORT™ PLUS ... a spring-loaded shield. Upon entry into a free ...
The SURGINEEDLE™ is a veress type needle that is used to insufflate the abdomen to create pneumoperitoneum....
... The complete line of Surgical Access ...unlike ... ,The OnePort™ trocar system is actually four ... versatile, operationally flexible and clinically adaptive to ... options in disposability and bladed or dilating ...
... The complete line of Surgical Access ...unlike ... ,The OnePort™ trocar system is actually four ... versatile, operationally flexible and clinically adaptive to ... options in disposability and bladed or dilating ...
Medicine Products: